Scientific Program

Chief, Group of Internal Clinics, Military Medical Academy, Clinic of Emergency Internal Medicine, Serbia.

Title: Increased thrombocyte activation is associated with clinical restenosis in patients who underwent percutaneous coronary intervention

Biography:

Nenad Ratkovic is Chief of Group of Internal Clinics, Military Medical Academy, Clinic of Emergency Internal Medicine, Belgrade, Serbia.

causes platelet activation. Some studies have demonstrated a relationship between the early thrombotic response and the later

development of restenosis. We investigated a relationship between circulating levels of soluble CD40 ligand (sCD40L) and soluble

P-selectin (sP-selectin) and appearance of restenosis as well as clinically manifested de novo coronary lesions in patients after PCI

procedure.

Methods: sCD40L and sP-selectin were measured in sera immediately before and 24 hours after PCI in overall 52 patients (22 urgent

PCI and 30 elective PCI, on dual antiplatelet therapy according to guidelines). Surveillance period for restenosis or de novo lesions

was 18 months.

Results: At the end of the surveillance period, 8 (15.4%) patients have had restenosis, 1 (2%) patient had acute stent thrombosis and

5 (10%) have had de novo clinically manifested coronary lesion. Patients with restenosis had a significantly higher increase in both

sCD40L (Δ-values: 0.81 (-0.19-3.28) vs. -0.65 (-2.25-0.00) ng/ml, p=0.002) and sP-selectine (Δ-values: 7.8 (-2.21-16.00) vs. 4.9 (-13.21-

0.65) ng/ml, p=0.01) compared with patients without restenosis. No statistically significant difference was noticed in sCD40L and

sP-selectin values in patients without restenosis compared with patients with de novo coronary lesions.

Conclusion: Circulating sCD40L and sP-selectin are markedly increased after PCI in patients who are prone for later development

of clinical restenosis, and not in patients who develop de novo coronary l APSTRAKT za ACCC 2015 percutaneous intervention

(PCI) with bare metal stent implantation causes platelet activation. Some studies have demonstrated a relationship between the early

thrombotic response and the later development of restenosis. We investigated a relationship between circulating levels of soluble

CD40 ligand (sCD40L) and soluble P-selectin (sP-selectin) and appearance of restenosis as well as clinically manifested de novo

coronary lesions in patients after PCI. sCD40L and sP-selectin were measured in sera immediately before and 24 hours after PCI in

overall 52 patients (22 urgent PCI and 30 elective PCI, on dual antiplatelet therapy ). Surveillance period was 18 months. 8 (15.4%)

patients have had restenosis, 1 (2%) patient had acute stent thrombosis and 5 (10%) have had de novo clinically manifested coronary

lesion. Patients with restenosis had a significantly higher increase in both sCD40L (Δ-values: 0.81 (-0.19-3.28) vs. -0.65 (-2.25-0.00)

ng/ml, p=0.002) and sP-selectine (Δ-values: 7.8 (-2.21-16.00) vs. 4.9 (-13.21-0.65) ng/ml, p=0.01) compared with patients without

restenosis. No statistically significant difference in patients without restenosis compared with patients with de novo lesions.

Circulating sCD40L and sP-selectin are markedly increased after PCI in patients who are prone for later development of clinical

restenosis and not in patients who develop de novo coronary lesions.